UT M.D. Anderson Cancer Center proposes to continue its role as a research base in the Community Clinical Oncology Program (CCOP).
The aim i s to establish a national network of CCOPs by generating broad spectrum clinical protocols, encompassing both cancer control and therapeutic scientific questions, that can be implemented in a community environment and provide data of the highest quality through a solid infrastructure of data management and quality control mechanisms. M.D. Anderson Cancer Center has served as a CCOP Research Base since 1986 and has generated a full program of Phase II and Phase III treatment protocols. In the past five years, 1,416 CCOP and affiliate patients were placed on clinical trial protocols. During this period, 2,339 patients were treated on M.D. Anderson cancer control protocols. A major thrust in M. D. Anderson cancer control program is to develop programs in the areas of chemoprevention, identification of high-risk individuals, nursing research focusing on symptom management and compliance, and pain control. In order to facilitate the development of concepts and protocols in this area, major CCOP/M.D. Anderson committees have been developed, including a Chemoprevention Working Group, the Community Oncology Nurse Investigator Network, and a CCOP Pain Task Force. A major innovation has been the extension of M.D. Anderson cancer control studies in the area of lung and head and neck chemoprevention studies into the Intergroup mechanism, with participation by all major cooperative groups in these studies. In developing the clinical trial and cancer control research programs, a Data Management Core has been established with full range of data collection, and computerized data base-capabilities. A quality assurance program, including both ongoing quality control assessments and periodic on-site audits, has been developed. All CCOPs are reviewed annually for performance, and recommendations for improvement or remedial action are made as necessary. The inclusion of CCOP program in the M.D. Anderson Comprehensive Cancer Center research program has proven to be a valuable extension of the scientific mission of the Center and is now viewed as an integral part of its research capability.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045809-12
Application #
2894737
Study Section
Special Emphasis Panel (SRC (15))
Project Start
1996-09-30
Project End
2001-05-31
Budget Start
1999-09-15
Budget End
2000-05-31
Support Year
12
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Levin, Victor A; Ictech, Sandra E; Hess, Kenneth R (2018) Clinical importance of eflornithine (?-difluoromethylornithine) for the treatment of malignant gliomas. CNS Oncol 7:CNS16
Narayan, Hari K; Wei, Wei; Feng, Ziding et al. (2017) Cardiac mechanics and dysfunction with anthracyclines in the community: results from the PREDICT study. Open Heart 4:e000524
Spencer, Christine N; Lopez, Gabriel; Cohen, Lorenzo et al. (2016) Nurse and patient characteristics predict communication about complementary and alternative medicine. Cancer 122:1552-9
Siefker-Radtke, Arlene O; Campbell, Matthew T; Munsell, Mark F et al. (2016) Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study. Urology 89:83-9
Kee, Bryan K; Morris, Jeffrey S; Slack, Rebecca S et al. (2015) A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Support Care Cancer 23:661-70
Mitri, Zahi; Karakas, Cansu; Wei, Caimiao et al. (2015) A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs 33:890-4
Minasian, Lori M; Tangen, Catherine M; Wickerham, D Lawrence (2015) Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program. Semin Oncol 42:748-63
Lewis, Mark A; Zhao, Fengmin; Jones, Desiree et al. (2015) Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study. J Pain Symptom Manage 49:1016-24
Oki, Yasuhiro; Ewer, Michael S; Lenihan, Daniel J et al. (2015) Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk 15:152-8
Bilen, Mehmet Asim; Johnson, Marcella M; Mathew, Paul et al. (2015) Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 121:69-76

Showing the most recent 10 out of 43 publications